$57.44
-0.10-0.17%
À la fermeture: -
$58.00
0.560.97%
Après les heures de négociation: 5:35 PM EDT
Comments
Loading...
Orientation et prévision
BioMarin Pharmaceutical publie des prévisions sur le BPA et les revenus futurs, donnant aux investisseurs un aperçu du montant que la société s'attend à gagner au cours des prochaines périodes.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
08/04/2025 | BMRN | BioMarin Pharmaceutical | FY | 2025 | $4.40 | $4.55 | $3.45 | $3.13B | $3.20B | $3.14B | |
05/16/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $3.45 | $3.10B | $3.20B | $3.14B | |
05/01/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $3.45 | $3.10B | $3.20B | $3.14B | |
02/19/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $3.45 | $3.10B | $3.20B | $3.14B | |
10/29/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.25 | $3.35 | $2.05 | $2.79B | $2.83B | $2.82B | |
09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.05 | $2.75B | $2.83B | $2.82B | |
09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2027 | — | — | — | $4.00B | $4.00B | — | |
08/05/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.05 | $2.75B | $2.83B | $2.82B | |
04/24/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.75 | $2.95 | $2.05 | $2.70B | $2.80B | $2.82B | |
02/22/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.60 | $2.80 | $1.96 | $2.70B | $2.80B | $2.83B | |
11/01/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.90 | $2.05 | $1.02 | $2.39B | $2.47B | $2.45B | |
07/31/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.85 | $2.10 | $1.02 | $2.38B | $2.50B | $2.46B | |
04/26/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $0.95 | $2.38B | $2.50B | $2.46B | |
02/27/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $1.61 | $2.38B | $2.50B | $2.58B | |
10/26/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.12B | |
08/03/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.11B | |
04/27/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.10B | |
02/23/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.14B | |
10/27/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.82B | $1.88B | $1.85B | |
07/28/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.79B | $1.88B | $1.82B | |
04/29/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.81B | |
02/25/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.91B |
FAQ
Quelles sont les dernières directives pour BioMarin Pharmaceutical (BMRN) ?
Les dernières prévisions pour BioMarin Pharmaceutical (BMRN) ont été communiquées le août 4, 2025 pour l'année complète 2025. L'entreprise a fourni des prévisions de bénéfice par action dans une fourchette de $4.40 à $4.55, par rapport à un BPA estimé de $3.45. De plus, BioMarin Pharmaceutical a prévu un chiffre d'affaires entre $3.13B et $3.20B pour le trimestre.
Parcourir guidance et prévisions sur toutes les actions.